ASPIRE-3-PREVENT: a cross-sectional survey of preventive care after a coronary event across the UK.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
04 2020
Historique:
received: 24 10 2019
revised: 03 02 2020
accepted: 26 02 2020
entrez: 2 5 2020
pubmed: 2 5 2020
medline: 15 12 2020
Statut: ppublish

Résumé

To quantify the implementation of the third Joint British Societies' Consensus Recommendations for the Prevention of Cardiovascular Disease (JBS3) after coronary event. Using a cross-sectional survey design, patients were consecutively identified in 36 specialist and district general hospitals between 6 months and 2 years, after acute coronary syndrome or revascularisation procedure and invited to a research interview. Outcomes included JBS3 lifestyle, risk factor and therapeutic management goals. Data were collected using standardised methods and instruments by trained study nurses. Blood was analysed in a central laboratory and a glucose tolerance test was performed. 3926 eligible patients were invited to participate and 1177 (23.3% women) were interviewed (30% response). 12.5% were from black and minority ethnic groups. 45% were persistent smokers, 36% obese, 52.9% centrally obese, 52% inactive; 30% had a blood pressure >140/90 mm Hg, 54% non-high-density lipoprotein ≥2.5 mmol/L and 44.3% had new dysglycaemia. Prescribing was highest for antiplatelets (94%) and statins (85%). 81% were advised to attend cardiac rehabilitation (86% <60 years vs 79% ≥60 years; 82% men vs 77% women; 93% coronary artery bypass grafting vs 59% unstable angina), 85% attended if advised; 69% attended overall. Attenders were significantly younger (p=0.03) and women were less likely to attend (p=0.03). Patients with coronary heart disease (CHD) are not being adequately managed after event with preventive measures. They require a structured preventive cardiology programme addressing lifestyle, risk factor management and adherence to cardioprotective medications to achieve the standards set by the British Association for Cardiovascular Prevention and Rehabilitation and JBS3 guidelines.

Identifiants

pubmed: 32354740
pii: openhrt-2019-001196
doi: 10.1136/openhrt-2019-001196
pmc: PMC7228656
pii:
doi:

Substances chimiques

Cardiovascular Agents 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

D Wood (D)
A Adamska (A)
S Adamska (S)
C Jennings (C)
K Kotseva (K)
A Hoye (A)
P Atkin (P)
D Fellowes (D)
A Negahban (A)
M Cunningham (M)
A Daniels (A)
L Zeidan (L)
S Iyer (S)
A Nicholson (A)
M Ocampo (M)
A Sevillano (A)
G Galasko (G)
L Benham (L)
S Preston (S)
D Sebastian (D)
S Lindsay (S)
C Atkinson (C)
C Kranilla (C)
M Vinod (M)
D Wood (D)
H Abbass (H)
N Rhoualmi (N)
Y Beerachee (Y)
C Bennett (C)
M Broome (M)
A Bwalya (A)
Lindsay Caygill (L)
L Dinning (L)
A Gillespie (A)
R Goodfellow (R)
J Guy (J)
T Idress (T)
C Mills (C)
C Morgan (C)
N Oustance (N)
N Singh (N)
M Yare (M)
J M Jagoda (JM)
H Bowyer (H)
V Christenssen (V)
A Groves (A)
P I Jan (PI)
A Riaz (A)
M Gill (M)
T A Sewell (TA)
D Gorog (D)
M Baker (M)
P De Sousa (P)
T Mazenenga (T)
J Shah (J)
A Banfield (A)
R Encarnado (R)
A Taylor (A)
C Travill (C)
S Gent (S)
N Hussain (N)
J Porter (J)
F Haines (F)
T Peachey (T)
J Taaffe (J)
K Wells (K)
D P Ripley (DP)
H Forward (H)
H McKie (H)
S L Pick (SL)
H E Thomas (HE)
P D Batin (PD)
D Exley (D)
T Rank (T)
J Wright (J)
A Kardos (A)
S-B Sutherland (SB)
L Wren (L)
P Leeson (P)
D Barker (D)
B Moreby (B)
J Sawyer (J)
J Sobolewska (J)
D Adams (D)
C Corbett (C)
K Hallett (K)
S Kaye (S)
L Morby (L)
L Winstanley (L)
J Stirrup (J)
M Brunton (M)
M M Gandhi (MM)
L Adams (L)
A Hunt (A)
L Tapp (L)
V Ansell (V)
S Hyndman (S)
A Brodison (A)
J Craig (J)
S Peters (S)
R Kaprielian (R)
A Bucaj (A)
K Mahay (K)
M Oblak (M)
A Sultan (A)
K Duell (K)
M Gaskell (M)
L Heaton (L)
C Moore (C)
V Parkinson (V)
T Taylor (T)
C Tierney (C)
K Vandesnepscheut-Jones (K)
A Broadley (A)
C Buckley (C)
L Matthews (L)
L Pippard (L)
C Gale (C)
M Pye (M)
Y McGill (Y)
H Redfearn (H)
M Fearnley (M)
K Lyons (K)
C Edwards (C)
L Miskelly (L)
S O Mullan (SO)
M Spencer (M)
E McCart (E)
P Donnelly (P)
S Kelly (S)
S Regan (S)
D Turnbull (D)
Dana Dawson (D)
B Brikinns (B)
S Joseph (S)
K Oldroyd (K)
F Teyhan (F)
J Kelly (J)
A Tewkesbury (A)
D Newby (D)
S Clark (S)
K Combe (K)
L Derr (L)
J Donnelly (J)
L Flint (L)
A Gill (A)
M Glenwright (M)
J Harrison (J)
H Nailon (H)
K Orr (K)
E McDonald (E)
C Mahoney (C)
F Morrow (F)
K Paterson (K)
B Poulose (B)
B Rif (B)
N Spath (N)
H Spence (H)
A Sutherland (A)
J Watt (J)
C Barr (C)
S Dekker (S)
D McDonald (D)
L O'Keeffe (L)
I Shread (I)
C C Lang (CC)
A M Choy (AM)
L Douglas (L)
S Kalra (S)
M Mohan (M)
R Symon (R)
J Halcox (J)
K Baldwin (K)
H Goldring (H)
C Thomas (C)
L Izzat (L)
D Evans (D)
Z Omar (Z)
E Perkins (E)

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Int J Cardiol. 2017 Apr 1;232:294-303
pubmed: 28094128
JAMA. 2003 Jul 2;290(1):86-97
pubmed: 12837716
Circulation. 2010 Feb 16;121(6):750-8
pubmed: 20124123
Eur J Prev Cardiol. 2019 May;26(8):824-835
pubmed: 30739508
Arch Intern Med. 2008 Oct 13;168(18):1950-60
pubmed: 18852395
BMJ. 2012 Jul 10;345:e4439
pubmed: 22782848
Eur J Prev Cardiol. 2014 Jan;21(1):98-106
pubmed: 22822180
Eur J Prev Cardiol. 2016 Apr;23(6):636-48
pubmed: 25687109
Lancet. 2016 Jun 18;387(10037):2507-20
pubmed: 27116918
Heart. 2014 Apr;100 Suppl 2:ii1-ii67
pubmed: 24667225
Eur Heart J. 1997 Oct;18(10):1569-82
pubmed: 9347267
Cochrane Database Syst Rev. 2014 Dec 12;(12):CD011273
pubmed: 25503364
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37
pubmed: 19287307
Arch Intern Med. 2005 Nov 28;165(21):2508-13
pubmed: 16314548
Heart. 2006 Jan;92(1):62-7
pubmed: 15797936
Eur J Prev Cardiol. 2014 Mar;21(3):366-76
pubmed: 23884981
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Heart. 2012 Jun;98(11):865-71
pubmed: 22581735
Eur Heart J. 2001 Apr;22(7):554-72
pubmed: 11259143
Eur Heart J. 2014 Jun 1;35(21):1411-20
pubmed: 24616337
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Eur Heart J. 2015 May 14;36(19):1171-7
pubmed: 25670820
Heart. 2017 Jun;103(11):840-847
pubmed: 28255098
Heart. 1996 Apr;75(4):334-42
pubmed: 8705756
Hypertension. 2018 Jun;71(6):1269-1324
pubmed: 29133354
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459

Auteurs

Catriona S Jennings (CS)

NHLI, Imperial College London, London, UK catriona.jennings@nuigalway.ie.
National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway, Galway, Ireland.

Kornelia Kotseva (K)

NHLI, Imperial College London, London, UK.
National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway, Galway, Ireland.

Paul Bassett (P)

NHLI, Imperial College London, London, UK.

Agnieszka Adamska (A)

NHLI, Imperial College London, London, UK.
National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway, Galway, Ireland.

David Wood (D)

NHLI, Imperial College London, London, UK.
National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway, Galway, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH